We aimed to describe patterns of continuous glucose monitoring (CGM) system use and glycemic outcomes from 2018 to 2020 in a large real-world cohort by analyzing anonymized data from US-based CGM users who transitioned from the G5 to the G6 System (Dexcom) in 2018. The main end points were persistent use, within-day and between-day utilization, hypoglycemia, time in range (TIR, 70–180 mg/dL [3.9–10 mmol/L]), and use of the optional calibration feature in 2019 and 2020. In a cohort of 31,034 individuals, rates of persistent use were high, with 27,932 (90.0%) and 26,861 (86.6%) continuing to upload data in 2019 and 2020, respectively. Compared with G5 use, G6 use was associated with higher device utilization, less hypoglycemia, higher TIR (in 2020), and >80% fewer calibrations in both 2019 and 2020 (P's < 0.001). High persistence and utilization of the G6 system may contribute to sustainable glycemic outcomes and decreased user burden.

中文翻译：

---

2018 年至 2020 年实时连续血糖监测系统的可持续使用

我们旨在通过分析从 G5 过渡到 G6 系统 (Dexcom) 的美国 CGM 用户的匿名数据，在一个大型真实世界队列中描述 2018 年至 2020 年连续血糖监测 (CGM) 系统使用和血糖结果的模式2018 年。主要终点是持续使用、日内和日间使用、低血糖、范围内时间（TIR，70-180 mg/dL [3.9-10 mmol/L]）和使用可选校准2019 年和 2020 年的特征。在 31,034 人的队列中，持续使用率很高，分别有 27,932 人（90.0%）和 26,861 人（86.6%）在 2019 年和 2020 年继续上传数据。与 G5 的使用相比，G6 的使用与更高的设备利用率、更少的低血糖、更高的 TIR（2020 年）以及 2019 年和 2020 年的校准减少 80% 以上有关（P's < 0.001)。G6 系统的高持久性和利用率可能有助于可持续的血糖结果和减少用户负担。